Suppr超能文献

氯离子通道CLC-K阻断/激活的分子开关:对高亲和力配体的最佳药效基团要求。

Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands.

作者信息

Liantonio Antonella, Picollo Alessandra, Carbonara Giuseppe, Fracchiolla Giuseppe, Tortorella Paolo, Loiodice Fulvio, Laghezza Antonio, Babini Elena, Zifarelli Giovanni, Pusch Michael, Camerino Diana Conte

机构信息

Unità di Farmacologia and Dipartimento Farmacochimico, Dipartimento Farmacobiologico, Facoltà di Farmacia, Università di Bari, Bari 70125, Italy.

出版信息

Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1369-73. doi: 10.1073/pnas.0708977105. Epub 2008 Jan 23.

Abstract

ClC-Ka and ClC-Kb Cl(-) channels are pivotal for renal salt reabsorption and water balance. There is growing interest in identifying ligands that allow pharmacological interventions aimed to modulate their activity. Starting from available ligands, we followed a rational chemical strategy, accompanied by computational modeling and electrophysiological techniques, to identify the molecular requisites for binding to a blocking or to an activating binding site on ClC-Ka. The major molecular determinant that distinguishes activators from blockers is the level of planarity of the aromatic portions of the molecules: only molecules with perfectly coplanar aromatic groups display potentiating activity. Combining several molecular features of various CLC-K ligands, we discovered that phenyl-benzofuran carboxylic acid derivatives yield the most potent ClC-Ka inhibitors so far described (affinity <10 microM). The increase in affinity compared with 3-phenyl-2-p-chlorophenoxy-propionic acid (3-phenyl-CPP) stems primarily from the conformational constraint provided by the phenyl-benzofuran ring. Several other key structural elements for high blocking potency were identified through a detailed structure-activity relationship study. Surprisingly, some benzofuran-based drugs inhibit ClC-Kb with a similar affinity of <10 microM, thus representing the first inhibitors for this CLC-K isoform identified so far. Based on our data, we established a pharmacophore model that will be useful for the development of drugs targeting CLC-K channels.

摘要

ClC-Ka和ClC-Kb氯离子通道对于肾脏盐重吸收和水平衡至关重要。人们越来越有兴趣寻找能够进行药理干预以调节其活性的配体。从现有的配体出发,我们采用了合理的化学策略,并结合计算建模和电生理技术,来确定与ClC-Ka上的阻断或激活结合位点结合的分子必要条件。区分激活剂和阻断剂的主要分子决定因素是分子芳香部分的平面度:只有具有完美共面芳香基团的分子才具有增强活性。结合各种CLC-K配体的多种分子特征,我们发现苯基-苯并呋喃羧酸衍生物产生了迄今为止所描述的最有效的ClC-Ka抑制剂(亲和力<10 microM)。与3-苯基-2-对氯苯氧基丙酸(3-苯基-CPP)相比,亲和力的增加主要源于苯基-苯并呋喃环提供的构象限制。通过详细的构效关系研究确定了其他几个具有高阻断效力的关键结构要素。令人惊讶的是,一些基于苯并呋喃的药物以<10 microM的相似亲和力抑制ClC-Kb,因此代表了迄今为止鉴定出的该CLC-K亚型的首批抑制剂。基于我们的数据,我们建立了一个药效团模型,这将有助于开发针对CLC-K通道的药物。

相似文献

引用本文的文献

4
Chloride transport modulators as drug candidates.氯离子转运调节剂作为药物候选物。
Am J Physiol Cell Physiol. 2021 Dec 1;321(6):C932-C946. doi: 10.1152/ajpcell.00334.2021. Epub 2021 Oct 13.
7
Taming unruly chloride channel inhibitors with rational design.通过合理设计驯服难以控制的氯离子通道抑制剂。
Proc Natl Acad Sci U S A. 2018 May 22;115(21):5311-5313. doi: 10.1073/pnas.1805589115. Epub 2018 May 7.
8
A selective class of inhibitors for the CLC-Ka chloride ion channel.一种选择性的 CLC-Ka 氯离子通道抑制剂。
Proc Natl Acad Sci U S A. 2018 May 22;115(21):E4900-E4909. doi: 10.1073/pnas.1720584115. Epub 2018 Apr 18.

本文引用的文献

4
Molecular physiology of renal ClC chloride channels/transporters.肾脏ClC氯离子通道/转运体的分子生理学
Curr Opin Nephrol Hypertens. 2006 Sep;15(5):511-6. doi: 10.1097/01.mnh.0000242177.36953.be.
5
Barttin modulates trafficking and function of ClC-K channels.Barttin调节ClC-K通道的转运和功能。
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11411-6. doi: 10.1073/pnas.0601631103. Epub 2006 Jul 18.
10
Function of chloride channels in the kidney.氯离子通道在肾脏中的功能。
Annu Rev Physiol. 2005;67:759-78. doi: 10.1146/annurev.physiol.67.032003.153547.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验